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testing both of these approaches in our models of arterial gene 
transfer. 
In conclusion, vascular gene transfer has the potential to 
produce profound local biologic effects without perturbing sys- 
temic physiology. In this role, gene transfer may eventually become 
a clinically useful targeted therapy for specific types of vascular 
disease. In 1996, however, substantial issues of efficiency, duration 
of expression, toxicity, arid long-term efficacy remain to be ad- 
dressed. The promise of viral gene therapy in the treatment of 
vascular disease is only now beginning to be clarified. 
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DIRECT TRANSFER- -  
NONVIRAL  APPROACHES 
ecNOS AND INT IMAL  HYPERPLASIA  
We have adopted a broad view of gene therapy as part of the 
emerging therapeutic armamentarium of molecular medicine in 
which DNA is used as a therapeutic agent of "drug" capable of 
modifying biologic or pathologic processes to ameliorate the 
course of disease. Accordingly, our objectives have been (1) to use 
the technology of genetic engineering toehicid~te he ftmdamental 
molecular mechanisms of cardiovascular disease and (2) to use 
DNA transfer technology to modify these pathobiologic processes 
in an attempt to develop novel therapeutic strategies that alter the 
natural history of cardiovascular disease. 
Although there are many strategies for modifying ene expres- 
sion in the intact animal, we have used modified liposomes as 
molecular delivery systems. In particular, we have adopted the use 
of Sendal virus hemagghiting virus of Japan (HVJ) conjugated to 
liposomes as a highly efficient method for introducing expression 
vector plasmids and oligonucleotides into cardiovascular tissues. 
We have successfully used this transfeetion system to modify gene 
expression within the vasculature, the kidney, the heart, and the 
liver. The efficacy of the HVJ-liposome system as a molecular 
delivery system will be discussed. This system may serve as a 
prototype of a molecular delivery system in which the proteins 
expressed by viruses that ordinarily facilitate cellular uptake are 
separated from the viral genome and employed in artificial DNA 
delivery complexes. We have successfully used this molecular 
delivery system to modulate vascular gene expression with antigene 
strategies such as antisense oligonucleotides or transcription factor 
cis element decoys as well as gene augmentation approaches using 
plasmid expression vectors. 
Our discussion will focus on several in vivo genetic engineering 
strategies that we have used to modify cell proliferation in the 
vasculature and the kidney, which may alter the natural history of 
vascular and glomerular diseases. We are intrigued by the observa- 
tion that acute manipulation of gene expression within the vessel 
;vail that arrests cell-cycle progression has long-term consequences 
on vascular function and structure. In particular, we will highlight 
the potential use of these genetic engineering strategies to create 
bioengineered vein grafts that are resistant to atherosclerosis. In 
further characterization f this intriguing phenomenon, we have 
observed that the long-term efficacy of our genetic engineering 
strategy in conferring antiatherogenic properties to the vein grafts 
is associated with the preservation f normal endothelial function as 
evidenced by nitric oxide generation. We are currently character- 
izing the molecular basis of this phenomenon. 
Many studies have documented the association betwccn vas~ 
cular disease and endothelial dysfunction; however, it remained to 
be demonstrated whether nitric oxide is actually an endogenous 
inhibitor ofvascular lesion formation in vivo. We dircctly tested this 
hypothesis by transfecting the endothelial cell-type nitric oxide 
synthase III gene into the vessel wall after balloon angioplasty 
injury as a gene therapy strategy to prevent restenosis. These studies 
provided the first direct evidence that nitric oxide inhibits vascular 
lesion formation in vivo. 
Although there are a number of potential gene therapy 
strategies for the treatment ofvascular disease, there is compelling 
evidence that he nitric oxide genes fulfill many of the characteristics 
of an ideal candidate. An important limitation of current ap- 
proaches to modulate gene expression within the vessel wall is the 
relatively low efficiency of all of the gene transfer methods used to 
date. The majority of cells within the vessel wall fail to express the 
gene therapy target gene. Therefore, gene therapy strategies that 
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rely on intracellular modulators of cell function will have inevitable 
limitations in efficacy based on the inefficiency of gene transfer. 
Recognizing this limitation, we devised astrategy that involved a 
naturally occurring endogenous substance that is highly diffusible 
and able to modulate the function of neighboring nontransfected 
cells within the vessel wall. This paracrine approach to gene therapy 
effectively amplifies the efficiency of the gene transfer in modulat- 
ing vascular function and structure. Our choice of genes that 
promote the generation ofthe vasodilator nitric oxide was based on 
its salutary effecti on the vascnlature, including its capacity to 
inhibit platelet aggregation, leukocyte adhesion, vascular smooth 
muscle cell growth and migration, and matrix production. Under 
certain circumstances nitric oxide may also promote selective cell 
deletion by inducing apoptosis. The efficacy of the gene transfer of 
nitric oxide synthase III confirms the utility of using a paracrine 
gene transfer strategy as a therapeutic approach to modulating 
vascular function and structure. Moreover, this experimental p- 
proach as provided new mechanistic insights into the biologic role 
of nitric oxide as an endogenous inhibitor of vascular lesion 
formation. Overall, the normalization of endothelial function by 
either genetic engineering strategies or more conventional phar- 
macologic approaches appears to be a particularly effective ap- 
proach to modulating the course of vascular disease. 
Gary If. Gibbons, MD 
Stanford University 
Stanford, Calif. 
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ANT ISENSE STRATEGIES  FOR CONTROLL ING 
THE VASCULAR RESPONSE TO IN JURY 
Antisense oligonucleotides have been proposed as being of impor- 
tance in treating and examining proliferative vascular diseases 
because of their potential ease of fabrication and intuitive intellec- 
tual appeal. Unlike complex proteins, oligonucleotides can be 
readily synthesized in a short time and in large bulk. The concept 
behind their use is especially intriguing iven the disappointing 
results of a multitude of other promising agents. Calcium channel 
blockers, antllipid agents, growth factors and their antagonists, 
antiplatelet agents, and antlinflammatory agents, among others, 
have all failed to inhibit ultimate neointimal hyperplasia n clinical 
trials despite initial enthusiastic data from experiments in culture 
and with lower anima! species. One major eason may be that higher 
animal species and human beings are not simple systems like 
isolated cells in culture. Redundant biologic processes enable the 
organism to recover from blockade of a single, specific pathway. An 
approach that seeks to identify and inhibit the common final 
pathway irrespective of the initial stimulus is therefore immensely 
appealing. Antisense approaches nable such an intervention, and 
a number of especially promising preliminary reports have been 
published. Yet the field remains incompletely defined and subject to 
substantial controversy. In particular it is still not clear which genes 
are best argeted incombating proliferative and accelerated vascular 
diseases; how to best direct, dose, and administer the antisense 
compounds to a given target sequence; and exactly how antisense 
oligonudeotides xert heir effects. We will now review these issues 
and controversies and attempt o offer a consensus opinion. A 
number of excellent reviews have recently been published that 
examine the field in full, and the reader is referred to them for more 
complete analysis beyond the scope of this manuscript. 1-4 
Identification of target 
It is now understood that intimal hyperplasia s the end result 
and inevitable consequence of a coordinated sequence of cellular 
events that include platelet adhesion, activation, and aggregation; 
the balance of endothelial integrity and dysfunction; leukocyte 
adhesion and transmigration; monocyte/macrophage transmigra- 
tion and transformation; lipid metabolism, including oxidation and 
methylation; growth factor and mitogen release, binding, internal- 
ization, and cell activation; smooth muscle cell migration and 
proliferation; and extracellular matrix production. Vascular smooth 
muscle cell activation is accompanied by the induction of several 
intracellular signal pathways, up-regulation of multiple receptors, 
and overexpression f a number of genes. The system's complexity 
and redundancy makes it difficult o envision asingle intervention 
that can control the entire process. Inhibition of one receptor may 
be overwhelmed by up-regulation or overexpression f another, 
and blockage of one pathway may be circumvented by overstimu~ 
lation of parallel, albeit circuitous, routes. Thus, many investigators 
have sought o inhibit one or more of the critical genes involved in 
cell-cycle progression. These have included enzymes involved in 
DNA and nucleotide synthesis, DNA binding proteins and tran- 
scription factors such as c-myb and c-myc, 5-12 and cell-cycle 
regulators including cdc-2, cdk-2, and the cyclins. 13-16 It is not yet 
dear whether the inhibition of one of these cycle controllers alone 
will suffice to limit the full extent ofintimal hyperplasia after injury. 
Indeed, the concomitant administration of antisense to cdc-2 
